Estimating the potential annual welfare impact of innovative drugs in use in Switzerland
Expenditures of health care systems are increasing from year to year. Therefore, this study aimed to estimate the difference in costs and benefits of innovative pharmaceuticals launched 2000 onwards compared to standard treatment on the national economy of Switzerland in 2010. The approach and formu...
Main Authors: | Matea ePavic, Alena ePfeil, Thomas eSzucs |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2014-05-01
|
Series: | Frontiers in Public Health |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fpubh.2014.00048/full |
Similar Items
-
Pharmacoeconomic analysis of the use of tocilizumab in therapy for rheumatoid arthritis:imitation simulation
by: Dmitry Vladimirovich Goryachev, et al.
Published: (2010-04-01) -
Cost-Utility Analysis: A Method of Quantifying the Value of Registered Nurses
by: Vanhook, Patricia M.
Published: (2007) -
Measuring the Benefits of Healthcare: DALYs and QALYs – Does the Choice of Measure Matter? A Case Study of Two Preventive Interventions
by: Federico Augustovski, et al.
Published: (2018-02-01) -
Exploring the potential cost-effectiveness of a vocational rehabilitation program for individuals with schizophrenia in a high-income welfare society
by: Stig Evensen, et al.
Published: (2019-05-01) -
The integrated care pathway for managing post stroke patients (iCaPPS©) in public primary care Healthcentres in Malaysia: impact on quality adjusted life years (QALYs) and cost effectiveness analysis
by: Aznida Firzah Abdul Aziz, et al.
Published: (2020-02-01)